share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%), etc.

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%), etc.

Avalo Therapeutics | SC 13G：超过5%持股股东披露文件-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%)等
SEC announcement ·  04/05 16:04
Moomoo AI 已提取核心信息
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin于2024年4月5日向美国证券交易委员会提交了附表13G，表示对Avalo Therapeutics, Inc.的114,775股股票拥有共同投票权和处置权。这占该公司普通股类别的9.99％。由于要收购符合申报门槛的股份，该文件是必需的。该文件指出，这些股票包括1,940.68125股C系列无表决权优先股和1,164,408份认股权证，均受益所有权上限为9.99％。该文件称，收购这些证券不是为了改变或影响Avalo Therapeutics, Inc.的控制权，也不是与任何具有该目的或效果的交易有关而持有的。申报人的主要业务办公室分别位于特拉华州、开曼群岛和美国。
Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin于2024年4月5日向美国证券交易委员会提交了附表13G，表示对Avalo Therapeutics, Inc.的114,775股股票拥有共同投票权和处置权。这占该公司普通股类别的9.99％。由于要收购符合申报门槛的股份，该文件是必需的。该文件指出，这些股票包括1,940.68125股C系列无表决权优先股和1,164,408份认股权证，均受益所有权上限为9.99％。该文件称，收购这些证券不是为了改变或影响Avalo Therapeutics, Inc.的控制权，也不是与任何具有该目的或效果的交易有关而持有的。申报人的主要业务办公室分别位于特拉华州、开曼群岛和美国。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息